PE17997A1 - Formulacion transdermica en parche del 3-[3-(hexiltio-1,2,5-tiadiazol-4-ilo]-1,2,5,6 tetrahidro-1-metil piridina - Google Patents
Formulacion transdermica en parche del 3-[3-(hexiltio-1,2,5-tiadiazol-4-ilo]-1,2,5,6 tetrahidro-1-metil piridinaInfo
- Publication number
- PE17997A1 PE17997A1 PE1996000081A PE00008196A PE17997A1 PE 17997 A1 PE17997 A1 PE 17997A1 PE 1996000081 A PE1996000081 A PE 1996000081A PE 00008196 A PE00008196 A PE 00008196A PE 17997 A1 PE17997 A1 PE 17997A1
- Authority
- PE
- Peru
- Prior art keywords
- tiadiazol
- piridine
- transdermic
- ilo
- methyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title abstract 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 abstract 1
- LFQSCWFLJHTTHZ-HQMMCQRPSA-N Ethanol-14C Chemical compound C[14CH2]O LFQSCWFLJHTTHZ-HQMMCQRPSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001499 parasympathomimetic effect Effects 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- OHHDIOKRWWOXMT-UHFFFAOYSA-N trazodone hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 OHHDIOKRWWOXMT-UHFFFAOYSA-N 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION QUE COMPRENDE 3-[3-(HEXILTIO-1,2,5-TIADIAZOL-4-ILO]-1,2,5,6 TETRAHIDRO-1-METIL PIRIDINA COMO INGREDIENTE ACTIVO; DE 0,1% A 10% P/P DE AZONA COMO VEHICULO QUE FACILITA LA PENETRACION; DE 30% A 69,8% P/P DE ETANOL; DE 29% A 50% P/P DE AGUA; DE 1% A 5% DE KLUCEL HF COMO AGENTE GELIFICADOR; Y OPCIONALMENTE HASTA 30% P/P DE PROPILENGLICOL; SE REFIERE TAMBIEN A OTRA COMPOSICION PREFERIDA QUE COMPRENDE DE 80%-85% A 97% P/P DE ETANOL, Y DE 2 A 15%-20% P/P DE KLUCEL HF. DICHAS FORMULACIONES SE ENCUENTRAN DISTRIBUIDAS EN UNA MATRIZ QUE COMPRENDE DE 88% A 99,8% P/P DEL ADHESIVO DE ACRILATO Y DE 0,1% A 35% CON RESPECTO AL PESO TOTAL DE LA MATRIZ DEL PRINCIPIO ACTIVO. LA FORMULACION TRANSDERMICA EN PARCHE PUEDE REDUCIR AL MINIMO LOS EFECTOS PARASIMPATICOMIMETICOS INDESEABLES, PROPORCIONANDO, NIVELES PLASMATICOS SOSTENIDOS DEL AGENTE FARMACEUTICAMENTE ACTIVO, EN TRATAMIENTOS COMO POR EJEMPLO LA ENFERMEDAD DE ALZHEIMER, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/390,447 US5605701A (en) | 1995-02-17 | 1995-02-17 | Transdermal formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE17997A1 true PE17997A1 (es) | 1997-06-04 |
Family
ID=23542490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1996000081A PE17997A1 (es) | 1995-02-17 | 1996-02-02 | Formulacion transdermica en parche del 3-[3-(hexiltio-1,2,5-tiadiazol-4-ilo]-1,2,5,6 tetrahidro-1-metil piridina |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5605701A (es) |
| EP (1) | EP0727209A2 (es) |
| AU (1) | AU4914396A (es) |
| IL (1) | IL116999A0 (es) |
| PE (1) | PE17997A1 (es) |
| WO (1) | WO1996025042A1 (es) |
| ZA (1) | ZA96796B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA199800535A1 (ru) * | 1995-12-07 | 1998-12-24 | Эли Лилли Энд Компани | Способ лечения боли |
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| US6475514B1 (en) | 1998-12-03 | 2002-11-05 | Andrew Blitzer | Athletic patch |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
| US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
| EP2334234A4 (en) | 2008-09-19 | 2013-03-20 | Tandem Diabetes Care Inc | DEVICE FOR MEASURING THE CONCENTRATION OF A SOLVED SUBSTANCE AND CORRESPONDING METHOD |
| US8758323B2 (en) | 2009-07-30 | 2014-06-24 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
| US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
| US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4855290A (en) * | 1985-05-10 | 1989-08-08 | State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research | Derivatives of quinuclidine |
| US5344656A (en) * | 1986-09-12 | 1994-09-06 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
| US4908027A (en) * | 1986-09-12 | 1990-03-13 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
| US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5260311A (en) * | 1989-02-22 | 1993-11-09 | Novo Nordisk A/S | Piperidine compounds and their use |
| US5043345A (en) * | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| US5264444A (en) * | 1989-02-22 | 1993-11-23 | Novo Nordisk A/S | Piperidine compounds and use |
-
1995
- 1995-02-17 US US08/390,447 patent/US5605701A/en not_active Expired - Fee Related
-
1996
- 1996-02-01 IL IL11699996A patent/IL116999A0/xx unknown
- 1996-02-01 EP EP96300711A patent/EP0727209A2/en not_active Withdrawn
- 1996-02-01 WO PCT/US1996/001490 patent/WO1996025042A1/en active Search and Examination
- 1996-02-01 AU AU49143/96A patent/AU4914396A/en not_active Abandoned
- 1996-02-01 ZA ZA9600796A patent/ZA96796B/xx unknown
- 1996-02-02 PE PE1996000081A patent/PE17997A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL116999A0 (en) | 1996-06-18 |
| US5605701A (en) | 1997-02-25 |
| EP0727209A2 (en) | 1996-08-21 |
| AU4914396A (en) | 1996-09-04 |
| WO1996025042A1 (en) | 1996-08-22 |
| ZA96796B (en) | 1997-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6455592B1 (en) | Use of hydrophilic penetration agents in dermatological compositions for the treatment of onychomycoses, and corresponding compositions | |
| US7198800B1 (en) | Compositions and methods | |
| ES2215918T3 (es) | Composiciones de esmalte de unas antimicotico. | |
| PE17997A1 (es) | Formulacion transdermica en parche del 3-[3-(hexiltio-1,2,5-tiadiazol-4-ilo]-1,2,5,6 tetrahidro-1-metil piridina | |
| ES2201361T3 (es) | Formulacion topica que contiene un tampon fosfato con estimulador de la permeabilidad cutanea. | |
| PE17397A1 (es) | Compuesto trans-dermico en parche del 3-[4-(hexiloxi)-1,2,5-tiadiazol-3-il]-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) | |
| ES2151968T3 (es) | Composiciones hemorroidales y metodo de utilizacion. | |
| DE69932158D1 (de) | Pharmazeutische zusammenstellungen | |
| UY25728A1 (es) | Peliculas consumibles oralmente que se disuelve rapidamente | |
| ES2242218T3 (es) | Composiciones farmaceuticas que contienen aceite de semilla del arbol candil. | |
| HN2004000232A (es) | " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden." | |
| PE17897A1 (es) | Formulacion transdermica en parche del 3-(4-butiltio)-1,2,5-tiadiazol-3-il)-1-azabiciclo (2,2,2) octano | |
| US20130210925A1 (en) | Subunguicide, and method for treating onychomycosis | |
| FI955403A0 (fi) | Valeltavia koostumuksia, jotka sisältävät polymeerimateriaalia, glykoleja ja glyseridejä | |
| ATE180671T1 (de) | Hydrierte rizinusöl-enthaltende injizierbare formulierungen mit verlängerter wirkstoffabgabe | |
| UY25192A1 (es) | Formulación medicamentosa con liberación controlada de sustancia activa | |
| AR002743A1 (es) | Esmalte de unas, y la utilizacion de dicho esmalte para la preparacion de un medicamento para el tratamiento de onicomicosis. | |
| AR044660A1 (es) | Composiciones farmaceuticas de atorvastatina | |
| AR025596A1 (es) | Composiciones insecticidas cuya materia activa es de tipo fenil-pirazol y procedimiento de lucha contra los insectos del suelo. | |
| ES2159038T3 (es) | Procedimiento de lucha contra los insectos con 1-fenilpirazoles o 1-heteroarilpirazoles. | |
| GT199800149A (es) | Formulaciones parasiticidas. | |
| DE69933671D1 (de) | Adenosin a1 antagonisten gegen männliche sterilität | |
| AR022899A1 (es) | Composiciones insecticidas sinergicas | |
| US20230310497A1 (en) | Disinfecting, skin-tolerable care agent for application to the skin | |
| CA2141703C (en) | Mouthwash |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |